Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled dose-ranging trial of polymerized depot house dust mite immunotherapy in allergic rhinoconjunctivitis
2016-002944-18Phase 2Terminated
- Sponsor
- BIAL
- Start
- Aug 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allergovac depot in allergic rhinoconjunctivitis (ARC) (4 arms), sponsored by BIAL. Started Aug 2016; status: terminated.
02
Drugs
allergovac depot
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2016-002944-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002944-18.